Bioretec Adjusts Financial Reporting for 2026-2028
Bioretec Ltd announced it will transition to reporting an adjusted sales margin beginning Q1 2026, enhancing transparency and aligning with industry standards. This change focuses on the profitability of implant sales before commercialization expenses. The updated financial targets for 2026-2028 will focus on this adjusted sales margin instead of the previously reported figures. Bioretec is a pioneer in biodegradable implant technologies and aims to transform orthopedic care worldwide.
Bioretec Ltd Company release 13 May 2026 at 14:00 p.m. EEST HELSINKI, May 13, 2026 /PRNewswire/ — To be aligned with industry reporting standards, Bioretec will transition to reporting an adjusted sales margin from Q1/2026 onwards, as compared to the previously reported sales margin. The…